POST-TEST

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The ongoing Phase III POLARIX trial is 5. On the Phase III ECHELON-1 trial, comparing the combination of polatu- which of the following regimens resulted zumab vedotin with R-CHP (, in a progression-free survival advantage cyclophosphamide, doxorubicin and in comparison to standard doxorubicin/ prednisone) to R-CHOP for patients with bleomycin/vinblastine/dacarbazine diffuse large B-cell lymphoma (DLBCL) (ABVD) as first-line therapy for patients in which setting? with Stage III or IV classical Hodgkin a. Previously untreated disease lymphoma? b. Relapsed/refractory (R/R) disease a. Bendamustine/ABVD c. Both previously untreated and R/R b. Nivolumab/ABVD disease c. /AVD d. Brentuximab vedotin/ nivolumab 2. Which of the following agents is a small molecule inhibitor of XPO1 that recently 6. What was demonstrated in terms of received FDA approval for the treatment progression-free survival in the Phase of R/R DLBCL on the basis of results III KEYNOTE-204 trial investigating from the Phase II SADAL trial? pembrolizumab versus brentuximab a. Tafasitamab vedotin for patients with R/R classical b. Selinexor Hodgkin lymphoma? c. Fostamatinib a. A statistically significant improve- d. ment with brentuximab vedotin e. Tazemetostat b. A statistically significant improve- ment with pembrolizumab 3. What was reported regarding the overall c. No statistically significant improve- and complete response rates with the ment between the treatment arms recently FDA-approved chimeric antigen receptor (CAR) T-cell therapeutic agent 7. After a median follow-up of approxi- brexucabtagene autoleucel (KTE-X19) for mately 18 months in the TRANSCEND patients with R/R mantle cell lymphoma NHL 001 trial of lisocabtagene on the Phase II ZUMA-2 trial? maraleucel for patients with R/R large a. High overall response rate B-cell lymphomas, median progression- with more than 50% complete free survival was not reached in which responses of the following patient groups? b. 50% overall response rate but no a. Patients who had received only 1 complete responses prior line of therapy c. Low overall response rate with no b. Patients who had achieved a complete responses complete response c. Patients younger than age 65 4. Which of the following drug types best describes the novel agent umbralisib? a. BTK (Bruton tyrosine kinase) inhibitor b. Bcl-2-targeted agent c. PI3 kinase inhibitor d. Antibody-drug conjugate

QID 3115 POST-TEST

Consensus or Controversy? Investigators Discuss Clinical Practice Patterns and Available Research Data Guiding the Management of Hematologic Cancers — Hodgkin and Non-Hodgkin Lymphoma (Faculty Presentations)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

8. Which of the following outcomes was 10. Which of the following agents recently reported for patients with follicular received FDA approval for patients with lymphoma (FL) in the interim analysis R/R FL with an EZH2 tumor mutation? of the Phase II ZUMA-5 trial of a. Mosunetuzumab axicabtagene ciloleucel for R/R indolent b. Zanubrutinib non-Hodgkin lymphoma, presented at c. Tafasitamab the 2020 ASCO virtual meeting? d. Tazemetostat a. An objective response rate higher than 90% e. Venetoclax b. No incidence of Grade 3 or higher cytokine release syndrome c. No incidence of Grade 3 or higher neurologic events d. All of the above

9. On the basis of the results of the RELEVANCE trial for patients with previously untreated advanced FL, which of the following regimens appears to have the same efficacy as rituximab/ ? a. Rituximab alone b. Rituximab/ (R2) c. Rituximab/obinutuzumab d. Rituximab/chlorambucil

QID 3115